肾输尿管切除术后手术诱导的慢性肾脏病对生存结局的影响
基于ROBUUST 2.0多中心回顾性注册研究,分析2006至2022年接受根治性肾输尿管切除术且基线无慢性肾脏病3-5期的上尿路尿路上皮癌患者1862例,发现34.7%和39.6%分别发生术后CKD-S3a和CKD-S3b,CKD-S3b与更差的全因死亡率相关,而CKD-S3a/3b均与癌症特异性死亡率无关。
要点
- 术后CKD-S3a和CKD-S3b发生率分别为34.7%和39.6%。
- CKD-S3b与更差的全因死亡率相关(HR 1.42,P=0.032),CKD-S3a无关。
- CKD-S3a和CKD-S3b均与癌症特异性死亡率无关。
核心结论
- 相当比例接受根治性肾输尿管切除术的上尿路尿路上皮癌患者发生手术诱导的慢性肾脏病。
- 发生CKD-S3b与更差的全因死亡率相关。
- 年龄增加、术前eGFR降低和化疗与发生CKD-S3b相关。
- 作者认为研究结果呼吁进一步探索和优化保留肾单位的手术策略及非肾毒性全身治疗以改善上尿路尿路上皮癌患者的生存结局。
研究设计与样本
- 利用ROBUUST 2.0注册数据库开展的多中心回顾性分析。
- 纳入2006年至2022年间接受根治性肾输尿管切除术且基线无慢性肾脏病3-5期的上尿路尿路上皮癌患者。
- 分析队列共1862例患者,按术后慢性肾脏病分期分层:无CKD-S(eGFR≥60 mL/min/1.73 m2)、CKD-S3a(eGFR 59-45 mL/min/1.73 m2)和CKD-S3b(eGFR<45 mL/min/1.73 m2)。
- eGFR采用慢性肾脏病流行病学协作组2021年公式计算。
- 主要结局为全因死亡率,采用logistic回归和Cox回归分别分析CKD-S3a/3b发生及全因死亡率/癌症特异性死亡率的预测因素,采用Kaplan-Meier分析各组总生存率和癌症特异性生存率。
主要发现
- 1862例患者中,34.7%(646例)发生CKD-S3a,39.6%(738例)发生CKD-S3b。
- CKD-S3b的预测因素包括年龄增加(OR 1.03,P=0.029)、术前eGFR降低(OR 1.06,P<0.001)、接受新辅助化疗(OR 2.07,P=0.006)和辅助化疗(OR 1.41,P=0.012)。
- 全因死亡率恶化与CKD-S3b相关(HR 1.42,P=0.032),与CKD-S3a无关(P=0.766)。
- CKD-S3a(P=0.812)和CKD-S3b(P=0.316)的发生均与癌症特异性死亡率无关。
- 5年总生存率在CKD-S3b组显著更差(无CKD组71%,CKD-S3a组70%,CKD-S3b组59%;P=0.017)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the prevalence, predictors and impact of surgically induced chronic kidney disease (CKD-S) on survival outcomes in patients with upper tract urothelial carcinoma (UTUC) following radical nephroureterectomy (RNU). METHODS: Utilising the ROBUUST 2.0 registry, a multicentre retrospective analysis was conducted in patients with UTUC undergoing RNU between 2006 and 2022 who did not have baseline chronic kidney disease (CKD) stages 3-5. We calculated the prevalence of postoperative CKD-S3a (estimated glomerular filtration rate [eGFR] 59-45 mL/min/1.73 m2) and CKD-S3b (eGFR <45 mL/min/1.73 m2) as measured by the Chronic Kidney Disease Epidemiology Collaboration 2021 equation. The analytical cohort was stratified by postoperative CKD stage [no CKD-S [eGFR ≥60 mL/min/1.73 m2]; CKD-S3a [eGFR 59-45 mL/min/1.73 m2] and CKD-S3b [eGFR <45 mL/min/1.73 m2]). The primary outcome was all-cause mortality (ACM). Predictors for development of CKD-S3a/3b and ACM/cancer-specific mortality (CSM) were analysed using logistic and Cox regression, respectively. Kaplan-Meier analysis was used to analyse overall survival (OS) and cancer-specific survival (CSS) among postoperative CKD groups. RESULTS: We analysed 1862 patients; 34.7% (646) and 39.6% (738), respectively, developed CKD-S3a and CKD-S3b. Predictors of CKD-S3b included increasing age (odds ratio [OR] 1.03, P = 0.029), decreasing preoperative eGFR (OR 1.06, P < 0.001) and receipt of neoadjuvant (OR 2.07, P = 0.006) and adjuvant chemotherapy (OR 1.41, P = 0.012). Worsened ACM was associated with CKD-S3b (hazard ratio 1.42, P = 0.032), but not CKD-S3a (P = 0.766). Development of CKD-S3a (P = 0.812) and CKD-S3b (P = 0.316) were not associated with CSM. The 5-year OS rate was significantly worse in CKD-S3b (no-CKD 71%, CKD-S3a 70%, CKD-S3b 59%; P = 0.017). No differences between CKD-S groups were noted for 5-year CSS (no-CKD 78%, CKD-S3a 77%, CKD-S3b 82%; P = 0.44). CONCLUSIONS: A significant proportion of UTUC patients undergoing RNU developed CKD-S. Development of CKD-S3b was associated with worse ACM. Increasing age, preoperative eGFR, and chemotherapy were associated with developing CKD-S3b. Our findings call for further exploration and refinement of nephron-preserving surgical strategies and non-nephrotoxic systemic therapy to improve survival outcomes in UTUC.
引用
- Puri D, Meagher MF, Wu Z, et al. The impact of post-nephroureterectomy surgically induced chronic kidney disease on survival outcomes. BJU Int. 2024. PMID: 39663586. doi:10.1111/bju.16569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。